WallStSmart

Avanos Medical Inc (AVNS)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 594% more annual revenue ($4.97B vs $715.90M). DXCM leads profitability with a 20.1% profit margin vs -10.4%. DXCM earns a higher WallStSmart Score of 74/100 (B).

AVNS

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 3.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: 1.24

DXCM

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.67

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVNS2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

Areas to Watch

AVNS4 concerns · Avg: 2.3/10
Market CapQuality
$1.17B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-8.9%2/10

ROE of -8.9% — below average capital efficiency

EPS GrowthGrowth
-21.7%2/10

Earnings declined 21.7%

Free Cash FlowQuality
$-16.60M2/10

Negative free cash flow — burning cash

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AVNS

The strongest argument for AVNS centers on Price/Book, Debt/Equity.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : AVNS

The primary concerns for AVNS are Market Cap, Return on Equity, EPS Growth.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

AVNS profiles as a turnaround stock while DXCM is a mature play — different risk/reward profiles.

AVNS carries more volatility with a beta of 1.57 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (74/100 vs 37/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Avanos Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Avanos Medical, Inc. is a medical technology company focused on providing medical device solutions to improve the quality of life for patients in North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company is headquartered in Alpharetta, Georgia.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?